Treatment with rHuEpo enables transfusion-free stem-cell autotransplantation.
© Copyright 2003 Clinical Oncology Week via NewsRx.com
In a recent study, scientists in Belgium "evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high-dose therapy (HDT), to allow autologous peripheral blood stem-cell transplantation (PBSCT) without red blood cell (RBC) transfusions."
"Eleven multiple myeloma patients underwent tandem HDT and autologous PBSC, receiving 500 U/kg/week rHuEpo from day 30 after initial transplant," explained F. Baron and coauthors at the University of Liege.
"Hemoglobin levels were 9.5±1.1 g/dL and 12.5±0.9 g/dL at the first and second transplant respectively (p<0.001)," they reported. "RBC transfusions were required for 10/11 patients for the first transplant versus 1/11 for the second (p<0.001)."
The researchers concluded that "a short course of rHuEpo therapy before HDT facilitates the performance of an autologous transplant without RBC transfusions."
Baron and colleagues published their study in the British Journal of Haematology (Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. Br J Haematol, 2003;123(1):103-105).
For additional information, contact Y. Beguin, University of Liege, CHU Sart Tilman, Department of Hematology, B-4000 Liege, Belgium.
Both O2- dependent, -independent mitochondrial signaling can occur during apoptosis in multiple myeloma cells.
c) Copyright 2003 Health & Medicine Week via NewsRx.com
"Superoxide (O2-) radicals have been linked to apoptosis. Here, we show that 2-methoxyestradiol (2ME2)-induced apoptosis in multiple myeloma (MM) cells is associated with O2- generation, whereas dexamethasone-(Dex)induced apoptosis occurs without concurrent increase in O2-," researchers in the United States report.
"In contrast, both these agents decrease mitochondrial transmembrane potential (deltapsim). Treatment of MM cells with an antioxidant N-acetyl-L-cysteine blocks 2ME2, but not Dex-induced apoptosis as well as release of mitochondrial proteins cytochrome c (cyto c) and Smac," wrote D. Chauhan and colleagues, Dana Farber Cancer Institute.
The researchers concluded: "Taken together, these results demonstrate that there are at least two distinct apoptotic pathways: one dependent on O2-, which is induced by 2ME2 and is associated with release of cyto c and Smac; and the other an independent of O2-, which is triggered by Dex and associated with Smac release."
Chauhan and colleagues published their study in Oncogene (Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene, 2003;22(40):6296-6300).
For additional information, contact K.C. Anderson, Dana Farber Cancer Institute, 44 Binney St., Boston, MA 02215, USA.
The angiogenic response in CAM assays is sometimes time-dependent.
(c) Copyright 2003 Blood Weekly via NewsRx.com
"In this study, we set out to make a fine characterization of the angiogenic response induced by plasma cells obtained from patients with active-multiple myeloma (MM), in comparison with cells obtained from patients with non-active MM and benign lesions such as monoclonal gammopathy of undetermined significance (MGUS), in the chick embryo chorioallantoic membrane (CAM) assay," according to researchers from Italy.
"To achieve this we investigated the time-course of the angiogenic response induced by gelatin sponges soaked in the cell suspensions and implanted on the CAM surface from day 8 to day 12 of incubation by evaluating the number of vessels, of the vessel bifurcation and the intervascular distance at 24, 48, 72 and 96 hours after the implants," wrote D. Ribatti and colleagues, Policlinic Bari, Department of Human Anatomy and Histology.
"The results show that plasma cell suspensions obtained from patients with active MM induce a vasoproliferative response that was significantly higher than that induced by cell suspensions obtained from patients with non-active MM or with MGUS, which is also a function of the day of implantation."
"In fact, implants made from day 8 to day 10 induce a strong angiogenic response, whereas those made from day 11 to day 12 do not. This finding might depend on the fact that CAM endothelium exhibits an intrinsically high mitotic rate until day 10. Thereafter, the endothelial mitotic index declines rapidly, and consequently cell suspensions implanted on the CAM of successively older embryos are not able to induce a vasoproliferative response in parallel with the reduced rates of growth of the CAM's endothelial cells," researchers concluded.
Ribatti and colleagues published their findings in Journal of Anatomy (In vivo time-course of the angiogenic response induced by multiple myeloma plasma cells in the chick embryo chorioallantoic membrane. J Anat, 2003;203(3):323-328).
Additional information can be obtained by contacting D. Ribatti, Policlin Bari, Department Human Anatomy & Histol, I-70124 Bari, Italy.